Acorah Software Products - Accounts Production19.3.600falsetruefalsetrueNo description of principal activity15 January 202531 January 202631 January 202616186670A Yusufiso4217:GBPiso4217:EURiso4217:USDxbrli:sharesxbrli:purexbrli:pure161866702025-01-14161866702026-01-31161866702025-01-152026-01-3116186670frs-core:CurrentFinancialInstruments2026-01-3116186670frs-bus:PrivateLimitedCompanyLtd2025-01-152026-01-3116186670frs-bus:FilletedAccounts2025-01-152026-01-3116186670frs-bus:Micro-entities2025-01-152026-01-3116186670frs-bus:AuditExempt-NoAccountantsReport2025-01-152026-01-3116186670frs-bus:Director12025-01-152026-01-31
Registered number: 16186670
Espiopharma Limited
Unaudited Financial Statements
For the Period 15 January 2025 to 31 January 2026
Ace Accountancy Services
Espiopharma Limited
Balance Sheet
As At 31 January 2026
Balance Sheet
Registered number: 16186670
31 January 2026
£
Current assets
9,866
Creditors: Amounts Falling Due Within One Year
(6,075)
NET CURRENT ASSETS
3,791
TOTAL ASSETS LESS CURRENT LIABILITIES
3,791
Accruals and deferred income
(1,200)
NET ASSETS
2,591
CAPITAL AND RESERVES
2,591
Notes
1.General Information
Espiopharma Limited is a private company, limited by shares, incorporated in England & Wales, registered number 16186670. The registered office is Flat 50 Broxholme House, Harwood Road, London, SW6 4AA.
2.Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
For the period ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.